{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T15:59:06Z","timestamp":1720540746810},"reference-count":27,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2406,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1600-0404.1995.tb00498.x","type":"journal-article","created":{"date-parts":[[2010,7,24]],"date-time":"2010-07-24T06:35:11Z","timestamp":1279953311000},"page":"35-39","source":"Crossref","is-referenced-by-count":1,"special_numbering":"supplement s162","title":["Rationalized polytherapy for epilepsy"],"prefix":"10.1155","volume":"92","author":[{"given":"P.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. R. M.","family":"Bittencourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/978-3-642-85921-2_1","volume-title":"Clinical pharmacology of anti-epileptic drugs","author":"GUELEN","year":"1975"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1157.1981.tb04327.x","article-title":"Monotherapy or polytherapy for epilepsy","volume":"22","author":"REYNOLDS","year":"1981","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB3|cit3","volume-title":"Studies on the clinical efficacy of marketed antiepileptic drugs","author":"COATSWORTH","year":"1971"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB4|cit4","article-title":"Statistical and theoretical considerations in the design of anti-convulsant trials. An analysis of 155 trials of phenytoin and carbama-zepine. Communication to the 12th International Epilepsy Symposium","author":"SHORVON","year":"1980","journal-title":"Copenhagen"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1528-1157.1975.tb06062.x","article-title":"Chronic anti-epileptic toxicity: a review","volume":"16","author":"REYNOLDS","year":"1975","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB6|cit6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.285.6356.1699","article-title":"Early prognosis of epilepsy","volume":"285","author":"SHORVON","year":"1982","journal-title":"BMJ"},{"issue":"suppl 1","key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1111\/j.1528-1157.1984.tb05642.x","article-title":"Valproate monotherapy","volume":"25","author":"HENRIKSEN","year":"1984","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/bmj.1.6111.474","article-title":"One drug for epilepsy","volume":"I","author":"SHORVON","year":"1978","journal-title":"BMJ"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB9|cit9","volume-title":"Prognosis in epilepsy, Springfield","author":"RODIN","year":"1968"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1212\/WNL.37.7.1111","article-title":"Phenytoin and carbamazepine, alone and in combination: anticonvulsant and neurotoxic effects","volume":"37","author":"MORRIS","year":"1987","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archneur.1983.04050120047006","article-title":"Valproate-ethosuximide combination therapy for refractory absence seizures","volume":"40","author":"ROWAN","year":"1983","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0163-7258(80)90047-9","article-title":"Serum levels of anticonvulsant drugs. Interpretation and clinical value","volume":"8","author":"REYNOLDS","year":"1980","journal-title":"Pharmacol Ther"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0140-6736(90)91886-F","article-title":"Established anticonvulsants and the treatment of refractory epilepsy","volume":"336","author":"BRODIE","year":"1990","journal-title":"Lancet"},{"issue":"suppl","key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0404.1992.tb04473.x","article-title":"New drugs for epilepsy: a rapidly changing scene","volume":"140","author":"RICHENS","year":"1992","journal-title":"Acta Neurol Scand"},{"issue":"suppl 2","key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB15|cit15","first-page":"60","article-title":"Randomized controlled pilot study of vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy an interim report","volume":"6","author":"KALVIAINEN","year":"1991","journal-title":"J Child Neurol"},{"issue":"suppl 1","key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB16|cit16","first-page":"87S","article-title":"Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy","volume":"27","author":"MUMFORD","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1528-1157.1991.tb04688.x","article-title":"Open, double-blind and long-term study of vigabatrin in chronic epilepsy","volume":"32","author":"REYNOLDS","year":"1991","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/jnnp.53.11.1008","article-title":"Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy","volume":"53","author":"SANDER","year":"1990","journal-title":"J Neurol Psychiat"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.38.5.743","article-title":"Effect of vigabatrin on epilepsy on mentally retarded patients: a 7 months follow-up study","volume":"38","author":"MATILAINEN","year":"1988","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB20|cit20","doi-asserted-by":"crossref","unstructured":"THOMPSON PJ. The effects of anticonvulsant drugs on the cognitive functions of normal volunteers and patients with epilepsy University of London 1981","DOI":"10.1111\/j.2044-8260.1981.tb00513.x"},{"issue":"suppl 2","key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1528-1157.1994.tb02447.x","article-title":"Vigabatrin - clinical evidence supporting rational polytherapy in the management of uncontrolled seizures","volume":"35","author":"BITTENCOURT","year":"1994","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0920-1211(90)90099-H","article-title":"A randomized double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment resistant partial seizures","volume":"7","author":"LOISEAU","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB23|cit23","volume-title":"Clinical update on lamotrigine: a novel anti-epileptic agent","author":"RICHENS","year":"1992"},{"issue":"suppl 6","key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB24|cit24","first-page":"116","article-title":"Open add-on trial of lamotrigine in refractory out-patients with epilepsy","volume":"34","author":"FUSTES","year":"1993","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1991.tb04689.x","article-title":"Double-blind study of gabapentin in the treatment of partial seizures","volume":"32","author":"SIVENIUS","year":"1991","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(94)90820-6","article-title":"Drug profile of gabapentin","volume":"343","author":"CHADWICK","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.1995.tb00498.x-BIB27|cit27","first-page":"505","volume-title":"Comprehensive epileptology","author":"JOHANNESSEN","year":"1990"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.1995.tb00498.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.1995.tb00498.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:46:38Z","timestamp":1671522398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.1995.tb00498.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,29]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.1995.tb00498.x","relation":{},"ISSN":["0001-6314","1600-0404"],"issn-type":[{"value":"0001-6314","type":"print"},{"value":"1600-0404","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,29]]}}}